The April 2025 U.S. tariff war has emerged as a pivotal factor reshaping the home health M&A market. Prior to the tariff announcement, home health dealmaking was on a recovery path – with strong strategic rationale underpinned by demographic trends, value-based care initiatives, and ample investor capital fueling